News und Analysen
LivaNova to Announce First-Quarter 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2022 results on Wednesday, May 4, 2022 at 1 p.m
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with
Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
LivaNova Announces 250th Unipolar Depression Patient Implanted in RECOVER Clinical Study
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 250th unipolar depression patient has been implanted in the RECOVER clinical study, “A P
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep Apnea
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the first patient implanted in the investigational device exemption (IDE) clinical study
LivaNova Reports Fourth-Quarter and Full-Year 2021 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2021.
For the fourth quarter of
Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (“siRNA”) therapeutics for the
Silence Therapeutics Announces SLN360 Phase 1 Data Accepted for Late-Breaking Presentation at the American College of Cardiology (ACC) Annual Scientific Session and Expo
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group Plc NPV
Routine Vaccination Rates in Teens and Adults Continue to Lag Behind Pre-Pandemic Levels, Follow-up Analysis Shows
Centers for Disease Control and Prevention (CDC)-recommended vaccinations for teens and adults continued to lag in 2020 and into the summer of 2021, according to a follow-up claims analysis
LivaNova to Announce Fourth-Quarter and Full-Year 2021 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2021 results on Wednesday, February
Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group Plc NPV
Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group Plc NPV
Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group plc
Form 8.3 - Maitland Institutional Services Limited: Form 8.3 - Clinigen Group plc
Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group Plc NPV
Form 8.3 - Maitland Institutional Services Limited: Re Clinigen Group Plc: Opening Position Disclosure
LivaNova to Present Scientific Data on VNS Therapy for Drug-Resistant Epilepsy at American Epilepsy Society 2021 Annual Meeting
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) Annual Meeting taking place December
LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the 4th International Brain Stimulation Conference, taking place
AstraZeneca: Rebound in 2024 with double-digit earnings growth
U.K.-based AstraZeneca PLC (NASDAQ: AZN) is up 8.95% in the past month as investors grow optimistic about the company's improved earnings outlook for 2024. Not only are sales of cancer and
3 stocks that crushed earnings estimates and still tanked
Stocks that crush their earnings estimates are supposed to go up. However, that's not always the case. Every earnings season, regardless of sector or industry, has its share of stocks that report
GSK is a remedy for the winter investment blahs
GSK (NYSE: GSK) is not immune to the patent cliff faced by the pharmaceutical industry, but it is about as well prepared as it can be. The company faces a smaller impact than others, has years to
Outcrop Silver & Gold to Present at Precious Metals Summit Zurich
Vancouver, British Columbia--(October 25, 2023) - Outcrop Silver & Gold (TSXV: OCG) (OTCQX: OCGSF) is pleased to announce its participation at the 2023 Precious Metals Summit Zurich where it
Outcrop Silver & Gold nimmt am Precious Metals Summit Zurich teil
Vancouver, British Columbia--(25. Oktober 2023) - Outcrop Silver & Gold (TSXV: OCG) (OTCQX: OCGSF) freut sich bekannt zu geben, dass das Unternehmen am Precious Metals Summit Zurich 2023